Thymosin Alpha-1 vs Larazotide acetate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ta1, Zadaxin
Thymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in a number of countries, including China and Italy, mainly for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with more than 30 trials and over 11,000 subjects.
Also: Larazotide, AT-1001
Larazotide is an 8-amino-acid oral peptide (GGVLVQPG) designed to tighten the junctions between gut lining cells, aimed at celiac disease. For years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. The honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 Meters Biopharma filed for Chapter 7 liquidation in July 2023. It is not approved anywhere.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymosin Alpha-1 | Larazotide acetate |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin alpha-1 works as an immune modulator rather than a stimulant, meaning it tries to rebalance the immune system rather than simply rev it up. It signals through toll-like receptors, particularly TLR9 and TLR2, on dendritic cells, which are the immune system's messengers. That signaling pushes naive T cells toward a Th1 (pathogen-fighting) profile, boosts natural killer cell activity, and improves antibody responses. At the same time it can promote regulatory T cells via the IDO pathway, which is why it is described as restoring balance: it can both wake up a sluggish immune response and dampen a dangerously overactive one. | Larazotide is modeled on a fragment of Vibrio cholerae zonula occludens toxin, a region that overlaps with zonulin, the human protein that loosens tight junctions in the gut wall. The idea is that it blocks zonulin signaling and helps tight junctions reassemble, so gluten fragments have a harder time slipping between cells into the tissue underneath, where they trigger the immune reaction in celiac disease. It acts locally in the gut lumen and is not meant to be absorbed. That is a reasonable hypothesis with lab and animal support, but it is worth being clear: larazotide does not stop the immune response to gluten itself, and no human trial proved it protects the gut lining on biopsy. |
| Common Dosing | 1.6 mg twice weekly 2-3x weekly | 0.5 mg three times daily before meals (trial dose) Three times daily, before meals |
| Administration | Subcutaneous injection | Oral capsule taken before meals, alongside a gluten-free diet (not instead of it) |
| Typical Duration | 6-12 months for hepatitis | 12 weeks of treatment in the phase 2b trial |
| Best Time to Take | Morning | About 15 minutes before each main meal (trial protocol) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with serious human trial data, but the results are mixed and worth reading honestly. Thymosin alpha-1 is approved abroad and widely used for chronic hepatitis B, often alongside interferon, and decades of use give it a strong safety record across more than 30 trials and over 11,000 subjects. The standout area is sepsis, and the story there is a cautionary tale: the earlier ETASS trial (Critical Care, 2013) hinted at lower 28-day mortality (26 percent versus 35 percent), but the much larger, better-designed TESTS phase 3 trial (BMJ, 2025, 1,106 patients at 22 Chinese centers, double-blind and placebo-controlled, dosed under the skin every 12 hours for 7 days) found no mortality benefit at all (23.4 versus 24.1 percent). It has also been studied as an add-on in certain cancers and in vaccine response, with weaker evidence. The honest summary: real drug, good safety, proven in hepatitis B, but several of its most-hyped uses did not survive a rigorous trial. | The key human study is a phase 2b trial published in Gastroenterology in 2015 (Leffler and colleagues, NCT01396213). It randomized 342 adults with celiac disease who still had symptoms on a gluten-free diet to 0.5 mg, 1 mg, or 2 mg three times daily or placebo for 12 weeks. Only 0.5 mg met the primary endpoint (symptom score 2.59 vs 2.88), with 26% fewer symptomatic days. The 1 mg and 2 mg doses did nothing measurable, an odd inverse dose response the authors could not explain (peptide aggregation was one guess), and most secondary endpoints missed. Safety looked similar to placebo. The phase 3 CedLara trial (NCT03569007) then tested the same 0.5 mg dose, but in June 2022 an interim analysis showed the number of patients needed to separate drug from placebo was too large to continue, and the trial was terminated. 9 Meters later pointed larazotide at COVID-related conditions such as MIS-C, then filed Chapter 7 in July 2023. We found no active development after that. Bottom line: one positive-ish phase 2b, one stopped phase 3, no approval. |
Frequently Asked Questions: Thymosin Alpha-1 vs Larazotide acetate
What is the difference between Thymosin Alpha-1 and Larazotide acetate?
Thymosin Alpha-1 is a immune peptide that thymosin alpha-1 (sold as zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. unlike most peptides in this space, it is a real, approved drug in a number of countries, including china and italy, mainly for chronic hepatitis b and as an immune booster, though it has never been approved by the fda in the united states. it has one of the larger human evidence bases of any peptide here, with more than 30 trials and over 11,000 subjects. Larazotide acetate is a immune peptide that larazotide is an 8-amino-acid oral peptide (ggvlvqpg) designed to tighten the junctions between gut lining cells, aimed at celiac disease. for years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. the honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 meters biopharma filed for chapter 7 liquidation in july 2023. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Alpha-1 or Larazotide acetate?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while Larazotide acetate is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Alpha-1 and Larazotide acetate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and Larazotide acetate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.